2933
Introduction:
Survival analysis need of large period of time for getting results. Survival subrogates variables provide with earlier data for clinical decisions. The current treatment paradigm is nowadays how the quality of the different treatment responses impact in patient's survival with the new treatment options. Azacitidine (AZA) is a hypomethilating agent which was available for clinical trials or compassionate use in Spain before receiving it marketing authorization in May 2009. We present the final analysis from those patients diagnosed with mielodysplastic syndromes (MDS) or acute myeloid leukemia (AML) selected from a longitudinal, multicenter Spanish patient registry.
Materials and Methods:
This analysis retrospectively gathers clinical data about the treatment, disease progression and survival of patients with MDS or AML who had received AZA 75mg/m2 in compassionate use conditions, with a dosage regimen documented. Three different dosage regimens at the beginning of each 28-day cycle were used; group A: days 1–5 (M-F)/group B: days 1–5, 8–9 (M-F, M-Tu)/group C: days 1–7 (M-Su). Survival analysis was stratified by patients' basal conditions, dosage schedule and best response after 4th and 6th cycles.
Results:
Data were collected from 200 patients with MDS or AML according to the WHO diagnostic criteria. Basal data, effectiveness results and data from haematological tolerance are mainly summarized in table 1. Median survival time was 706 days (95% CI 588–1093) in those patients who achieved a response versus 225 days (95% CI 156–319) in those who did not. Survival analysis showed differences based on the best response achieved (p<0.0001), the response achieved after the 4th cycle (p<0.0001) and the response achieved after the 6th cycle (p<0.0001). Survival Hazard Ratios based on the best response, the responses after 4th and 6th cycles are summarized in table 2. Figures 1 and 2 shows survival curves based on best response after 4 and 6 cycles of therapy.
Conclusions:
These in routine clinical practice data confirms those survival data previously published. Although results of AZA-001 show CR is sufficient but not necessary to prolong OS; our data shows an increase in the risk of not being alive when decreasing the quality of the best response achieved by patients during the treatment. To achieve the best response after the 4th cycle could be an AZA treatment goal.
Percentages (Chi-Square Test, Exact's Fisher Test, LR Test according to application criteria met), Median +/− IQR (Kruskal-Wallis Test) or Median +/− Std (T-Test) when applicable.
Disclosures:
García: Celgene: Research Funding. de Miguel LLorente:Celgene: Speakers Bureau. Bargay:Celgene: Research Funding. Ramos:Celgene: Speakers Bureau. Sanz:Celgene: Speakers Bureau. Sánchez:Celgene: Speakers Bureau.
Background: Background: Acute Myeloid Leukemias arising after cytotoxic therapy (t-AML) or with myelodysplasia-related changes (AML-MRC) share adverse risk features and poor outcomes after standard 3+7 chemotherapy. In a randomized clinical trial, CPX-351 has shown superior overall survival (OS) compared to standard anthracyclinecytarabine schedule in these AML subtypes.
Aims:Aims: to evaluate the effectiveness of CPX-351 treatment in a real-world setting.
Methods:Methods: adult t-AML and AML-MRC patients who have been treated upfront with CPX-351 in 35 Spanish centers between 2018 and 2021. All patients were included in the PETHEMA registry (NCT02606825). Primary end-point was OS. Secondary end points were complete remission with or without hematological recovery (CR/CRi), proportion of minimal residual negativity (MRD), rate of allogeneic hematopoietic stem cell transplant (HSCT) and safety.
Results: Results:CPX-351 was administered to 74 patients as first induction chemotherapy. Median age was 67 (63-71) years, with 40% (30/74) of female patients. ECOG performance status score was 0-1 in 85% (53/62) patients. A diagnosis of t-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.